Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 32, 2021 - Issue 1
Submit an article Journal homepage
701
Views
8
CrossRef citations to date
0
Altmetric
Psoriasis and dermatitis

Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis

Mwangi J. MurageEli Lilly and Company, Indianapolis, IN, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2769-3188View further author information
ORCID Icon,
Adrienne M. GilliganConcertoHealthAI, Fort Worth, TX, USA; View further author information
,
Oth TranIBM Watson Health, Cambridge, MA, USA; View further author information
,
Orin GoldblumEli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Russel BurgeEli Lilly and Company, Indianapolis, IN, USA; ;University of Cincinnati, Cincinnati, OH, USA; View further author information
,
Chen-Yen LinEli Lilly and Company, Indianapolis, IN, USA; View further author information
&
Abrar QureshiThe Warren Alpert Medical School of Brown University, Providence, RI, USAView further author information
 show all
Pages 56-63 | Received 10 Oct 2019, Accepted 01 Nov 2019, Published online: 20 Nov 2019

References

  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
  • Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658.
  • Menter A, Gottlieb A, Feldman SR. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment. J Am Acad Dermatol. 2008;58(5):826–850.
  • Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
  • Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.
  • Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23.
  • Hu Y, Chen Z, Gong Y, et al. A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis. Clin Drug Investig. 2018;38(3):191–199.
  • Farahnik B, Beroukhim K, Zhu TH, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6(1):25–37.
  • TALTZ ixekizumab injection, solution. Prescribing information. Indianapolis (IN): Eli Lilly and Company; [cited 2019 Nov 8]. Available from: http://uspl.lilly.com/taltz/taltz.html#pi.
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
  • Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. PPA. 2018;12:1483–1503.
  • Mucha L, Masia NA, Axelsen KJ. Per-patient-per-month drug costs in Medicare Part D protected classes. Pharmacoeconomics. 2006;24(S3):79–84.
  • Palmer JB, Li Y, Herrera V, et al. Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord. 2016;17(1):261.
  • Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. JMCP. 2004;10(2):159–165.
  • Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. JMCP.. 2015;21(3):201–209.
  • Murage MJ, Anderson A, Casso D, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatolog Treat. 2018;30(2):1–9.
  • Cao Z, Carter C, Wilson KL, et al. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2015;26(2):113–120.
  • Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
  • Schwartzman S, Li Y, Zhou H, et al. Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clin Rheumatol. 2017;36(7):1579–1588.
  • Hyde K, Cardwell LA, Stotts R, et al. Psoriasis treatment cost comparison: biologics versus home phototherapy. Am J Pharm Ben. 2018;10(1):18–21.
  • Gilligan AM, Franchino-Elder J, Song X, et al. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anitocagulants. Curr Med Res Opin. 2018;34(2):285–295.
  • Kong AM, Farahbakhshian S, Pendergraft T, et al. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis. Curr Med Res Opin. 2017;33(10):1869–1877.
  • Pesa JA, Muser E, Montejano LB, et al. Costs and resource utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes. 2015;2(4):377–385.
  • Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661–669.
  • Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2(1):12.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.